The technology of lipid nanoparticles has a long history in drug delivery, which begins with the discovery of liposomes by Alec D Bangham in the 1960s. Since then, numerous studies have been conducted on these systems, and several nanomedicinal products that utilize them have entered the market, with the latest being the COVID-19 vaccines. Despite their success, many aspects of their biophysical behavior are still under investigation. At the same time, their combination with other classes of biomaterials to create more advanced platforms is a promising endeavor. Herein, we developed mixed lipid-polymer nanoparticles with incorporated curcumin as a drug delivery system for therapy, and we studied its interactions with various biosystems. Initially, the nanoparticle physicochemical properties were investigated, where their size, size distribution, surface charge, morphology, drug incorporation and stability were assessed. The incorporation of the drug molecule was approximately 99.8 % for a formulated amount of 10 % by weight of the total membrane components and stable in due time. The association of the nanoparticles with human serum albumin and the effect that this brings upon their properties was studied by several biophysical techniques, including light scattering, thermal analysis and circular dichroism. As a biocompatibility assessment, interactions with erythrocyte membranes and hemolysis induced by the nanoparticles were also studied, with empty nanoparticles being more toxic than drug-loaded ones at high concentrations. Finally, interactions with bacterial membrane proteins of Staphylococcus aureus and the antibacterial effect of the nanoparticles were evaluated, where the effect of curcumin was improved when incorporated inside the nanoparticles. Overall, the developed mixed nanoparticles are promising candidates for the delivery of curcumin to infectious and other types of diseases.
Keywords: Biophysical interactions; Curcumin; Erythrocytes; Human serum albumin; Polymer-grafted mixed/hybrid liposomes; Staphylococcus aureus.
Copyright © 2022 Elsevier B.V. All rights reserved.